Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025? | Manifold

Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?

Plus

25

Ṁ1266

2026

30%

chance

1D

1W

1M

ALL

Since the first FDA approval for weight loss, GLP-1 receptor agonists are in the news as new blockbuster drugs.

As of today, neither Novo Nordisk's Ozempic / Wegovy (Semaglutid), nor Eli Lilly's Mounjaro / Tirzepatid are projected to generate more 2023 sales than Merck's Keytruda (Pembrolizumab, a checkpoint inhibitor used in tumor therapy).

This market will resolve YES if a GLP-1 agonist is the best-selling drug in 2025 (new sales) per reliable company or media reports.

This question is managed and resolved by Manifold.

#️ Technology

#Weight loss drugs

Get

1,000

and

3.00

Sort by:

Does "bestselling" mean "top dollar value" or, like, doses sold?

Does it count if the drug hits multiple targets and one of the targets is GLP-1R agonism? For example, tirzepatide targets both the GLP-1 and GIP receptors.

predictedNO

@Tossup I'm inclined to include cases like that

I am betting under the assumption that this is about global sales, as you did not specify any single country.

@WXTJ Yes, global sales

Based very directly on this from @habakuk

Related questions

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?

Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025

What fraction of US adults will regularly take GLP-1 drugs in 2030?

Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss

Affordable weight loss drugs before 2030?

[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...

Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?

Related questions

Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027

What fraction of US adults will regularly take GLP-1 drugs in 2030?

Will Ozempic/GLP-1 Agonists become an issue with a clear partisan divide in the US in the next 5 years?

Will Donald Trump ever take a GLP-1 agonist (eg Ozempic, Mounjaro, Wegovy, Zepbound, etc) for weight loss

Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?

Affordable weight loss drugs before 2030?

Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?

[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...

Ozempic will NOT be the leading GLP-1 agonist by total $ US sales by December 31, 2025

Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?

© Manifold Markets, Inc.•Terms + Mana-only Terms•Privacy•Rules